Allergy Territory Account Specialist









Maybe it has to do with the customer type that supports 98% of CSU patients....Allergists. But you still sound smart.
CSU is the lead indication, but food allergy and more might follow in the future. Remibrutinib has the potential to become a blockbuster very fast. Consider just using 2 Remibrutinib tablets instead of an EpiPen. In comparison to Omalizumab BTK inhibitors appear to have rapid onset and transient effects offering the potential for intermittent use to prevent IgE mediated anaphylaxis.